Amarin Corporation plc is a biopharmaceutical company with expertise in lipid science focused on the commercialization and development of therapeutics to improve cardiovascular health. The Company�s lead product, Vascepa (known in its development stage as AMR 101), reduces triglyceride levels in adult patients with severe hypertriglyceridemia. The Company is developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol (LDL-C) levels, referred as mixed dyslipidemia. REDUCE-IT is a multi-center, prospective, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effectiveness of Vascepa. The REDUCE-IT study is designed to evaluate the efficacy of Vascepa in reducing major cardiovascular events in an at-risk patient population also receiving statin therapy. The Company completed dosing of AMR102, a fixed dose combination of Vascepa and a leading statin product.